Published in Mol Cancer on November 14, 2009
Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med (2012) 1.62
Epigenetics of colorectal cancer. Gastroenterology (2012) 1.60
MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer (2011) 1.59
Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS One (2012) 1.58
An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality. Int J Cancer (2014) 1.42
MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells. PLoS One (2016) 1.39
Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics (2013) 1.39
Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res (2010) 1.36
Novel classes of non-coding RNAs and cancer. J Transl Med (2012) 1.35
Identifying microRNA-mRNA regulatory network in colorectal cancer by a combination of expression profile and bioinformatics analysis. BMC Syst Biol (2012) 1.35
Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med (2012) 1.34
Epigenetics and colorectal cancer pathogenesis. Cancers (Basel) (2013) 1.33
Circulating microRNA is a biomarker of pediatric Crohn disease. J Pediatr Gastroenterol Nutr (2011) 1.29
MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease. Immune Netw (2011) 1.29
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology (2015) 1.24
The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression. PLoS One (2013) 1.22
The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PLoS One (2011) 1.20
MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol (2012) 1.16
MiRNA-based therapeutic intervention of cancer. J Hematol Oncol (2015) 1.14
Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol (2012) 1.14
Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.14
The Role of MicroRNAs in Regulatory T Cells and in the Immune Response. Immune Netw (2011) 1.13
MicroRNAs-role in lung cancer. Dis Markers (2014) 1.11
Integrated microRNA and mRNA expression profiling in a rat colon carcinogenesis model: effect of a chemo-protective diet. Physiol Genomics (2011) 1.10
Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis (2013) 1.07
Molecular events in primary and metastatic colorectal carcinoma: a review. Patholog Res Int (2012) 1.07
MicroRNA function and dysregulation in bone tumors: the evidence to date. Cancer Manag Res (2014) 1.07
The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut (2015) 1.03
Expression of the ribonucleases Drosha, Dicer, and Ago2 in colorectal carcinomas. Virchows Arch (2011) 1.03
Exosome can prevent RNase from degrading microRNA in feces. J Gastrointest Oncol (2011) 1.01
Dicer and miRNA in relation to clinicopathological variables in colorectal cancer patients. BMC Cancer (2011) 1.00
The next thing in prognostic molecular markers: microRNA signatures of cancer. Gut (2010) 0.99
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer (2014) 0.99
The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. BMC Cancer (2012) 0.98
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. Clin Exp Metastasis (2014) 0.95
MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44. J Exp Clin Cancer Res (2014) 0.94
Dysregulation of microRNAs in colonic field carcinogenesis: implications for screening. PLoS One (2012) 0.93
MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J Gastroenterol (2014) 0.93
Grape seed extract efficacy against azoxymethane-induced colon tumorigenesis in A/J mice: interlinking miRNA with cytokine signaling and inflammation. Cancer Prev Res (Phila) (2013) 0.93
Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer (2012) 0.92
MicroRNAs as Novel Biomarkers in Colorectal Cancer. Front Genet (2012) 0.92
Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients. Biomed Res Int (2014) 0.91
Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells. Int J Colorectal Dis (2012) 0.90
MiR-203 suppresses ZNF217 upregulation in colorectal cancer and its oncogenicity. PLoS One (2015) 0.90
Differential miRNA expression in the mouse jejunum during garlic treatment of Eimeria papillata infections. Parasitol Res (2011) 0.90
Serum microRNAs: A new diagnostic method for colorectal cancer. Biomed Rep (2013) 0.89
MicroRNAs in Human Diseases: From Lung, Liver and Kidney Diseases to Infectious Disease, Sickle Cell Disease and Endometrium Disease. Immune Netw (2011) 0.89
KITENIN-targeting microRNA-124 suppresses colorectal cancer cell motility and tumorigenesis. Mol Ther (2014) 0.89
Circulating cell-free microRNAs as biomarkers for colorectal cancer. Surg Today (2015) 0.88
Therapeutic evaluation of microRNAs by molecular imaging. Theranostics (2013) 0.88
MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application. J Transl Med (2012) 0.88
A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clin Cancer Res (2014) 0.88
MicroRNA-5p and -3p co-expression and cross-targeting in colon cancer cells. J Biomed Sci (2014) 0.87
Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status. Oncotarget (2015) 0.87
Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. Oncotarget (2015) 0.86
MicroRNAs 146a and 147b biomarkers for colorectal tumor's localization. Biomed Res Int (2014) 0.86
Micromanaging the classification of colon cancer: the role of the microRNAome. Clin Cancer Res (2011) 0.85
Regulation of UHRF1 by microRNA-9 modulates colorectal cancer cell proliferation and apoptosis. Cancer Sci (2015) 0.85
Colorectal tumor molecular phenotype and miRNA: expression profiles and prognosis. Mod Pathol (2016) 0.84
The pro-apoptotic role of the regulatory feedback loop between miR-124 and PKM1/HNF4α in colorectal cancer cells. Int J Mol Sci (2014) 0.83
Site-specific associations between miRNA expression and survival in colorectal cancer cases. Oncotarget (2016) 0.83
Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohort. Br J Cancer (2014) 0.83
Gene-Diet Interactions on Colorectal Cancer Risk. Curr Nutr Rep (2012) 0.83
Preoperative low dose NSAID treatment influences the genes for stemness, growth, invasion and metastasis in colorectal cancer. Int J Oncol (2014) 0.83
Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition. Antioxid Redox Signal (2014) 0.83
Aldose reductase inhibition prevents colon cancer growth by restoring phosphatase and tensin homolog through modulation of miR-21 and FOXO3a. Antioxid Redox Signal (2012) 0.83
Mechanistic insights into the role of microRNAs in cancer: influence of nutrient crosstalk. Front Genet (2012) 0.83
miRNAs as biomarkers for management of patients with colorectal cancer. Biomark Med (2010) 0.83
Screening miRNAs for early diagnosis of colorectal cancer by small RNA deep sequencing and evaluation in a Chinese patient population. Onco Targets Ther (2016) 0.81
microRNAs: An Emerging Paradigm in Lung Cancer Chemoresistance. Front Med (Lausanne) (2015) 0.81
microRNA-17 Is the Most Up-Regulated Member of the miR-17-92 Cluster during Early Colon Cancer Evolution. PLoS One (2015) 0.81
Chemokine receptor CCR6 expression is regulated by miR-518a-5p in colorectal cancer cells. J Transl Med (2014) 0.81
Manipulating miRNA Expression: A Novel Approach for Colon Cancer Prevention and Chemotherapy. Curr Pharmacol Rep (2015) 0.79
Nutrient-Gene Interaction in Colon Cancer, from the Membrane to Cellular Physiology. Annu Rev Nutr (2016) 0.79
Identifying miRNA/mRNA negative regulation pairs in colorectal cancer. Sci Rep (2015) 0.79
High blood sugar levels significantly impact the prognosis of colorectal cancer patients through down-regulation of microRNA-16 by targeting Myb and VEGFR2. Oncotarget (2016) 0.79
Recent advances in colorectal cancer research: the microenvironment impact. Cancer Microenviron (2011) 0.79
Fecal Tests: From Blood to Molecular Markers. Curr Colorectal Cancer Rep (2011) 0.79
Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer. PLoS One (2016) 0.78
MicroRNA Expression Profiling to Identify and Validate Reference Genes for the Relative Quantification of microRNA in Rectal Cancer. PLoS One (2016) 0.78
The anti-miR21 antagomir, a therapeutic tool for colorectal cancer, has a potential synergistic effect by perturbing an angiogenesis-associated miR30. Front Genet (2014) 0.78
Epigenetic regulation of the intestinal epithelium. Cell Mol Life Sci (2015) 0.78
Quantitation of microRNA-92a in colorectal adenocarcinoma and its precancerous lesions: Co-utilization of in situ hybridization and spectral imaging. Oncol Lett (2014) 0.78
Detection of miRNA as non-invasive biomarkers of colorectal cancer. Int J Mol Sci (2015) 0.78
Study on the molecular regulatory mechanism of MicroRNA-195 in the invasion and metastasis of colorectal carcinoma. Int J Clin Exp Med (2015) 0.78
Identification of associations between small molecule drugs and miRNAs based on functional similarity. Oncotarget (2016) 0.78
The Role of Bioactive Dietary Components in Modulating miRNA Expression in Colorectal Cancer. Nutrients (2016) 0.77
Implications of miRNAs in Colorectal Cancer Chemoresistance. Int Drug Discov (2015) 0.77
Upregulation of miR-99a is associated with poor prognosis of acute myeloid leukemia and promotes myeloid leukemia cell expansion. Oncotarget (2016) 0.77
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer (2014) 0.77
Predictive Biomarkers to Chemoradiation in Locally Advanced Rectal Cancer. Biomed Res Int (2015) 0.77
miR-155 Regulated Inflammation Response by the SOCS1-STAT3-PDCD4 Axis in Atherogenesis. Mediators Inflamm (2016) 0.76
Chemoprotective epigenetic mechanisms in a colorectal cancer model: Modulation by n-3 PUFA in combination with fermentable fiber. Curr Pharmacol Rep (2015) 0.76
Microbial Disruption of Autophagy Alters Expression of the RISC Component AGO2, a Critical Regulator of the miRNA Silencing Pathway. Inflamm Bowel Dis (2015) 0.76
Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-125b is involved in the anti-migration/invasion effects of arsenic trioxide on human chondrosarcoma. J Exp Clin Cancer Res (2016) 0.76
Mechanisms by Which Pleiotropic Amphiphilic n-3 PUFA Reduce Colon Cancer Risk. Curr Colorectal Cancer Rep (2014) 0.76
MicroRNAs in Liver Disease: Bench to Bedside. J Clin Exp Hepatol (2013) 0.76
Development of a deregulating microRNA panel for the detection of early relapse in postoperative colorectal cancer patients. J Transl Med (2016) 0.76
Molecular mechanisms underlying application of serum procalcitonin and stool miR-637 in prognosis of acute ischemic stroke. Am J Transl Res (2016) 0.75
Genetic Association of Hematopoietic Stem Cell Transplantation Outcome beyond Histocompatibility Genes. Front Immunol (2017) 0.75
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell (1993) 33.79
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res (2008) 20.59
Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res (2003) 17.13
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol (2009) 11.50
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene (2007) 10.79
A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep (2008) 10.71
EGFR antagonists in cancer treatment. N Engl J Med (2008) 9.68
MicroRNAs in Cancer. Annu Rev Med (2009) 9.37
Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut (2009) 8.98
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol (2008) 7.27
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
MicroRNA expression and function in cancer. Trends Mol Med (2006) 7.02
p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol (2007) 6.87
Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res (2007) 6.57
Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer (2006) 6.39
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A (2008) 6.24
miR-21: a small multi-faceted RNA. J Cell Mol Med (2009) 5.59
Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A (2007) 5.50
microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38
Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA (2007) 5.35
MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol (2008) 5.21
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res (2007) 4.95
Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem (2006) 4.57
let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull (2006) 4.42
Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology (2008) 4.38
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle (2008) 4.35
Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res (2008) 4.20
The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol (2008) 4.10
Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res (2008) 3.81
p53 enters the microRNA world. Cancer Cell (2007) 3.78
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A (2007) 3.59
Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res (2008) 3.06
Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem (2007) 2.55
The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer (2008) 2.52
mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer (2007) 2.40
Prognostic Values of microRNAs in Colorectal Cancer. Biomark Insights (2006) 2.35
Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol (2009) 2.34
Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis (2008) 2.12
Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis (2008) 2.09
Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther (2008) 2.07
MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res (2008) 2.03
In situ detection of precursor and mature microRNAs in paraffin embedded, formalin fixed tissues and cell preparations. Methods (2008) 1.98
Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics Proteomics (2006) 1.94
Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res (2008) 1.72
Colorectal cancer: genetics of development and metastasis. J Gastroenterol (2006) 1.63
The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis (2009) 1.60
Epithelial-mesenchymal transition mediated tumourigenesis in the gastrointestinal tract. World J Gastroenterol (2008) 1.51
Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway. J Cell Physiol (2009) 1.45
microRNAs: a new emerging class of players for disease diagnostics and gene therapy. J Cell Mol Med (2007) 1.43
Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res (2007) 1.37
Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. Int J Oncol (2008) 1.36
The brave new world of RNA. Nature (2002) 1.22
The impact of microRNAs on colorectal cancer. Virchows Arch (2009) 1.20
MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg (2009) 1.13
MicroRNAs, ultraconserved genes and colorectal cancers. Int J Biochem Cell Biol (2009) 0.94
Insulin pathway related genes and risk of colorectal cancer: INSR promoter polymorphism shows a protective effect. Endocr Relat Cancer (2007) 0.88
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol (2006) 2.57
Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev (2012) 2.47
Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med (2012) 1.62
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood (2003) 1.55
MicroRNA involvement in glioblastoma pathogenesis. Biochem Biophys Res Commun (2009) 1.45
Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res (2010) 1.36
Novel classes of non-coding RNAs and cancer. J Transl Med (2012) 1.35
Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med (2012) 1.34
MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci (2011) 1.28
Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer (2012) 1.26
Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer. J Cell Mol Med (2012) 1.24
MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol (2012) 1.16
Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol (2012) 1.14
MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol (2012) 1.11
MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol (2012) 1.08
microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol (2010) 1.07
MicroRNAs and glioblastoma: roles in core signalling pathways and potential clinical implications. J Cell Mol Med (2011) 1.02
MicroRNAs and their target gene networks in renal cell carcinoma. Biochem Biophys Res Commun (2011) 1.01
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Med Oncol (2012) 1.00
Numerical defects in CD8+CD28- T-suppressor lymphocyte population in patients with type 1 diabetes mellitus and multiple sclerosis. Cell Immunol (2010) 1.00
Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer. Cancer Biomark (2012) 0.98
Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance? Neuropathology (2011) 0.97
Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Res (2008) 0.92
Autologous adipose tissue-derived stromal vascular fraction cells application in patients with osteoarthritis. Cell Transplant (2015) 0.91
Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity? J Neuroimmunol (2010) 0.91
MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J Cancer Res Clin Oncol (2013) 0.91
Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells. Int J Colorectal Dis (2012) 0.90
Common polymorphisms in GSTM1, GSTT1, GSTP1, GSTA1 and susceptibility to colorectal cancer in the Central European population. Eur J Med Res (2012) 0.88
Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review. Cardiovasc Toxicol (2012) 0.87
Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy. J Cell Mol Med (2012) 0.86
Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Int J Oncol (2012) 0.84
Human myeloid dendritic cells for cancer therapy: does maturation matter? Vaccine (2010) 0.84
BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy. Tumour Biol (2015) 0.83
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry. BMC Gastroenterol (2014) 0.83
Therapeutic dendritic cell-based cancer vaccines: the state of the art. Crit Rev Immunol (2013) 0.83
Modeling effect of the septic condition and trauma on C-reactive protein levels in children with sepsis: a retrospective study. Crit Care (2007) 0.83
The role of Aktand RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells. Leuk Lymphoma (2002) 0.83
Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up. Support Care Cancer (2005) 0.83
Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs. Cancer Biother Radiopharm (2010) 0.83
Dendritic cells and their role in tumor immunosurveillance. Innate Immun (2012) 0.83
Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients. Eur J Pediatr (2005) 0.83
AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients. Dis Markers (2013) 0.83
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wien Klin Wochenschr (2010) 0.82
Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations. J Neurol Sci (2012) 0.81
Expression pattern of HLA class I antigens in renal cell carcinoma and primary cell line cultures: methodological implications for immunotherapy. Med Sci Monit (2009) 0.81
Surface-enhanced laser desorption ionization/time-of-flight mass spectrometry reveals significant artifacts in serum obtained from clot activator-containing collection devices. Clin Chem (2006) 0.81
Temporal gene expression profile of human precursor B leukemia cells induced by adhesion receptor: identification of pathways regulating B-cell survival. Blood (2002) 0.79
Multifunctional immune-modulatory protein HLA-E identified in classical Hodgkin lymphoma: possible implications. Pathol Res Pract (2011) 0.79
Delivery of large heterologous polypeptides across the cytoplasmic membrane of antigen-presenting cells by the Bordetella RTX hemolysin moiety lacking the adenylyl cyclase domain. Infect Immun (2012) 0.79
Multiple gene-to-gene interactions in children with sepsis: a combination of five gene variants predicts outcome of life-threatening sepsis. Crit Care (2014) 0.79
Identification of microRNAs regulated by isothiocyanates and association of polymorphisms inside their target sites with risk of sporadic colorectal cancer. Nutr Cancer (2013) 0.79
Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Med Oncol (2012) 0.78
High frequency of temperature-sensitive mutants of p53 in glioblastoma. Pathol Oncol Res (2013) 0.78
Dendritic cell-based immunotherapy for the treatment of hematological malignancies. Hematology (2003) 0.77
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. BMC Cancer (2014) 0.77
Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry. BMC Public Health (2012) 0.76
Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data. Future Oncol (2015) 0.75
[In Process Citation]. Klin Onkol (2015) 0.75
Dynamic stress echocardiography in asymptomatic patients who received chemotherapy in childhood because of a malignant disease. Kardiol Pol (2003) 0.75
[Editorial]. Klin Onkol (2016) 0.75
Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma. Anticancer Res (2014) 0.75
DIOS - database of formalized chemotherapeutic regimens. Stud Health Technol Inform (2013) 0.75
[Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute]. Klin Onkol (2009) 0.75
[A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors]. Klin Onkol (2008) 0.75
[Clinical aspects of trastuzumab treatment in breast cancer]. Klin Onkol (2009) 0.75
[Editorial]. Klin Onkol (2015) 0.75